Bactiguard Holding AB’s Annual and Sustainability Report 2024
The Annual and Sustainably Report 2024 for Bactiguard Holding AB (publ) is now available at ir.bactiguard.com/
In 2024, Bactiguard completed the strategic shift needed to enable the company to be the premier choice for both current and future partners. This transformation delivered positive financial results and positioned Bactiguard for growth. The company achieved EBITDA profitability, which was a core commitment to its shareholders, along with positive cash flow from operating activities. Reaching these milestones marks a significant achievement, allowing Bactiguard to further develop its business and infection prevention technology platform. Most importantly, it validated the strength of the company’s business model and license-focused strategy.
“Through our license-focused strategy, we strive to be the premier partner for leading MedTech companies by delivering our knowledge and capabilities to enhance partner medical devices. Continuously strengthening our core competences remains essential to deepening partnerships and is a top priority for us also going forward. The synergies are clear – driving positive outcomes for our license partners also benefits Bactiguard, healthcare providers, and patients alike.” Christine Lind comments in his CEO statement.
Read more in Bactiguard Holding AB’s Annual and Sustainability Report 2024 here
Bactiguard Holding AB (publ) is obliged to make this information public under the Securities Markets Act. The information was submitted for publication at 07.00 CET on 17 April 2025.
For more information, please contact:
Patrick Bach, CFO +46 761 295 911
Nina Nornholm, Head of Communication & Investor Relations +46 708 550 356
About Bactiguard
Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company’s unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard’s infection prevention technology and solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.
Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. The company also has a portfolio of wound management products. Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.
Read more about Bactiguard: www.bactiguard.com
Follow Bactiguard on LinkedIn
